United States Patent 11,324,710: Tretinoin Lotion Claims, Orange Book Position, and Generic Entry Risk

U.S. Patent No. 11,324,710 protects a narrowly defined once-daily method of treating acne vulgaris with a 0.01% to 1% tretinoin lotion containing specified polymeric emulsifiers, carbomer viscosity agents, soluble collagen, sodium hyaluronate, oil, and water. Its commercial relevance is tied to Altreno Lotion, 0.05% tretinoin, marketed by Almirall through the Ortho Dermatologics business.

The patent is primarily a formulation-specific method-of-use patent. It does not broadly cover every topical tretinoin product, every acne treatment, or every tretinoin lotion. Infringement risk is highest for a generic product that reproduces the claimed excipient architecture and is labeled for once-daily treatment of acne vulgaris.

What does U.S. Patent 11,324,710 protect?

The independent claim requires all of the following elements:

Claim element	Scope
Disease	Acne vulgaris
Use	Applying the composition once daily
Active ingredient	Tretinoin at 0.01% to 1% by weight
Polymeric emulsifier	Cross-linked copolymer of acrylic acid and C10-C30 alkyl acrylate
Emulsifier concentration	0.02% to 0.08% by weight
Viscosity agent	Cross-linked homopolymer of acrylic acid
Viscosity-agent concentration	0.1% to 2% by weight
Moisturizer	Soluble collagen and sodium hyaluronate
Moisturizer concentration	5% to 10% by weight
Oil phase	One or more oils at 1% to 3.5% by weight
Vehicle	Water
Dosage form	Lotion

The claim is cumulative. A competing product outside any one required limitation is outside the literal scope of claim 1, although the doctrine of equivalents could affect products with insubstantial formulation differences.

The patent does not claim tretinoin as a molecule. Tretinoin is an established retinoid with long-standing prior art and multiple approved topical products. The patent instead targets a particular vehicle and administration regimen.

How narrow is the composition scope?

The claim is narrower than a conventional “tretinoin lotion” claim because it requires both polymer systems and a defined moisturizing package.

The first polymer must be a cross-linked acrylic acid/C10-C30 alkyl acrylate copolymer. Claim 3 narrows this element to carbomer copolymer type B. The second polymer must be a cross-linked acrylic acid homopolymer. Claim 7 narrows it to carbomer homopolymer type A.

The composition therefore requires two distinct rheology or emulsion-control components:

A cross-linked copolymer used as the polymeric emulsifier.
A cross-linked acrylic-acid homopolymer used as the viscosity-increasing agent.

A formulation containing only one carbomer, a non-cross-linked polymer, or a different emulsifier may avoid literal infringement if the product also avoids the remaining claim limitations.

The moisturizing limitation is also material. The composition must contain both soluble collagen and sodium hyaluronate, with the combined moisturizing agent present at 5% to 10% by weight. A product using glycerin alone, hyaluronic acid alone, or another emollient system may not satisfy this limitation.

What do the dependent claims add?

Claims 2 through 14 define commercially relevant subranges and ingredient selections.

Claim	Limitation
2	Tretinoin at 0.05%
3	Carbomer copolymer type B as emulsifier
4	Broad list of mineral oils, petrolatum, fatty alcohols, esters, and triglycerides
5	Mineral oil, light mineral oil, petrolatum, or combination
6	Oil component consists of mineral oil
7	Carbomer homopolymer type A as viscosity agent
8	Viscosity agent at 0.4% to 1%
9	Viscosity agent at 0.6% to 1%
10	Viscosity of 2,500 to 18,000 cP
11	Viscosity of 8,000 to 12,000 cP
12	Preservatives, antioxidants, and/or humectants
13	Neutralizing agent maintaining pH at 5 to 6
14	Detailed 0.05% tretinoin formulation with defined excipient ranges

Claim 14 is the most commercially specific claim. It requires:

0.05% tretinoin;
0.05% carbomer copolymer type B;
0.6% to 1% carbomer homopolymer type A;
mineral oil up to 3%, subject to the 1% minimum inherited from claim 1;
soluble collagen and sodium hyaluronate at 5% to 10%;
glycerin at 5% to 20%;
butylated hydroxytoluene at 0.1% to 2%;
octoxynol-9 at 0.05% to 0.5%;
optional benzyl alcohol and/or methyl paraben;
optional trolamine.

Because claim 14 depends through claims 12 and 10, the claim also carries the viscosity limitation of 2,500 to 18,000 cP. It does not automatically require the pH limitation in claim 13 because claim 14 does not depend on claim 13.

What product is associated with Patent 11,324,710?

The claimed formulation corresponds closely to Altreno Lotion, 0.05% tretinoin. The FDA-approved product is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. The label directs once-daily application to affected areas, consistent with the core administration limitation in claim 1 (FDA, 2018).

Product	Active ingredient	Dosage form	Approved indication	Commercial relevance
Altreno Lotion	Tretinoin 0.05%	Lotion	Acne vulgaris	Closely aligned with claims 1, 2, and 14
Retin-A Cream/Gel	Tretinoin, various strengths	Cream or gel	Acne vulgaris and related uses	Older reference products
Tretinoin microsphere products	Tretinoin, generally 0.04% or 0.1%	Gel	Acne vulgaris	Different delivery and vehicle technology
Generic tretinoin cream or gel	Multiple strengths	Cream or gel	Acne vulgaris	Not automatically within the patent claims

The product-level analysis depends on the formulation, not the label name. A generic 0.05% tretinoin product is not necessarily infringing. It must also contain the claimed polymer, moisturizer, oil, water, and lotion characteristics.

What is the FDA and Orange Book status?

Altreno was approved under NDA 209475 on October 26, 2018. It is a prescription topical product, not a biologic, so biosimilar provisions do not apply. A competing applicant would generally pursue an abbreviated new drug application rather than a biosimilar application.

The relevant regulatory framework is an ANDA supported by pharmaceutical equivalence and bioequivalence data. For a topical lotion, the generic applicant must address formulation sameness or permitted differences, product performance, manufacturing controls, and labeling.

Patent listings associated with a branded topical product can create a Paragraph IV certification issue. If Patent 11,324,710 is listed in the Orange Book for the relevant Altreno NDA, an ANDA applicant seeking approval before the patent expiry would need to certify that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger a 45-day period for the NDA holder to bring an infringement action under the Hatch-Waxman framework (21 U.S.C. § 355(j)).

The patent number alone does not establish the current Orange Book listing status. Orange Book status can change through delisting, patent-term adjustments, listing corrections, or NDA-holder updates. The relevant inquiry is the current FDA patent-listing record for NDA 209475.

When does Patent 11,324,710 lose exclusivity?

Patent 11,324,710 issued on May 10, 2022. Its enforceable term is determined by the earliest effective nonprovisional filing date in its priority chain, subject to patent-term adjustment, terminal disclaimer, patent-term extension, and any applicable regulatory exclusivity.

The patent appears to belong to the Altreno formulation family, whose relevant patent family term is generally associated with a June 2035 expiry date. A precise enforceable expiry date must be taken from the USPTO patent-term calculation and any applicable Orange Book entry.

FDA regulatory exclusivity is separate from patent exclusivity. Altreno received approval in 2018, so the principal commercial barrier is the patent estate and formulation differentiation rather than a current new-drug exclusivity period.

What Paragraph IV challenges and litigation affect the patent?

A Paragraph IV challenge would be directed at one or more of the following positions:

The claims are anticipated by prior tretinoin lotion or emulsion formulations.
The claimed combination would have been obvious from known carbomer, mineral-oil, collagen, sodium-hyaluronate, and tretinoin systems.
The patent specification does not adequately support the full claimed concentration ranges.
The claims lack enablement across the entire range of tretinoin, polymer, oil, moisturizer, and viscosity values.
The proposed generic does not practice all elements of the asserted method claims.
The patent is unenforceable because of inequitable conduct or improper listing, if supported by evidence.

The strongest noninfringement argument is likely formulation-based. A generic applicant could use a different emulsifier, replace soluble collagen, use a different viscosity system, omit mineral oil, formulate as a gel or cream, or avoid a once-daily acne-vulgaris label. Each change would need to be assessed against the full claim and the doctrine of equivalents.

No reliable litigation conclusion should be drawn from the patent number alone. A complete litigation assessment requires reviewing PACER, the USPTO Patent Center file history, FDA Orange Book submissions, and any ANDA notice letters.

How strong is the patent estate?

The patent estate is strongest against a product that intentionally copies the Altreno formulation.

Strengths

Claim 1 combines active ingredient, excipient identity, quantitative ranges, dosage form, disease, and dosing frequency.
Claims 2, 3, 6, 7, 9, 11, and 14 create fallback positions around a commercially plausible 0.05% formulation.
The claims are directed to a topical product where formulation identity can be investigated through regulatory disclosure, reverse engineering, and product-performance testing.
The claim set captures both the composition and its once-daily acne use.

Weaknesses

The independent claim is crowded with limitations.
A generic can potentially design around individual excipients or concentration ranges.
Tretinoin, carbomers, mineral oil, glycerin, and topical acne treatment are old technical elements.
Method claims can be harder to enforce against an ANDA product if the proposed labeling omits the claimed use or dosing instruction.
The terms “lotion,” “soluble collagen,” “carbomer copolymer type B,” and “carbomer homopolymer type A” may require claim-construction analysis.

The estate is therefore commercially meaningful but not a broad barrier to all tretinoin competition.

What generic launch scenarios exist?

Scenario	Generic product profile	Patent risk	Likely commercial effect
Direct copy	0.05% tretinoin lotion with the claimed excipients and once-daily acne label	High	Paragraph IV litigation likely
Formulation design-around	Different emulsifier, viscosity agent, moisturizer, or oil	Lower, subject to equivalents	May require additional development and bridging work
Different dosage form	Cream, gel, microsphere gel, or foam	Lower under the asserted claims	Competes with Altreno but may not be therapeutically identical
Label carve-out	Omits once-daily acne use where legally and regulatorily supportable	Reduced method-claim risk	Limits marketing scope
Post-expiry entry	Product satisfies ANDA requirements and launches after patent expiry	Low patent risk	Full-price erosion risk to the branded lotion

The most credible generic strategy is a formulation design-around rather than a direct copy. The commercial tradeoff is that changing collagen, sodium hyaluronate, carbomer type, oil phase, or viscosity may require additional development work and could reduce substitutability with Altreno.

How does this patent compare with competing tretinoin patent estates?

Older tretinoin products generally rely on expired or aging formulation and delivery patents. Their commercial competition comes from generic creams, gels, microsphere products, and newer vehicles. Patent 11,324,710 differs because it protects a specific lotion architecture linked to a modern branded product.

Patent category	Typical protected subject matter	Relevance to Patent 11,324,710
Active ingredient patents	Tretinoin compound	Generally not relevant; tretinoin is long-established
Basic formulation patents	Cream, gel, or emulsion composition	Prior-art and validity background
Microsphere patents	Controlled-release or encapsulated tretinoin	Technically distinct from the claimed lotion
Method-of-use patents	Acne treatment, dosing, or patient population	Claim 1 combines treatment and composition restrictions
Manufacturing patents	Mixing, homogenization, stability, or packaging	Can create separate process barriers
Current Altreno-family patents	Specific lotion formulation and use	Directly relevant

Biosimilar risk is immaterial. Tretinoin is a small-molecule active ingredient, and competing products enter through the generic-drug pathway.

What manufacturing and IP barriers remain?

The patent does not expressly claim a manufacturing process. A manufacturer could therefore avoid this patent while producing a similar product if the final formulation does not meet the claimed limitations. Separate manufacturing patents, trade secrets, know-how, supplier agreements, stability data, and regulatory comparability requirements may still create practical barriers.

The most sensitive manufacturing variables are:

polymer hydration and neutralization;
order of addition;
control of viscosity;
dispersion of tretinoin in the oil or aqueous phase;
protection from light and oxidation;
preservation;
uniformity across the batch;
final pH between 5 and 6 where applicable.

These process details may be protected through unpublished know-how even where they are not claimed in Patent 11,324,710.

Key Takeaways

Patent 11,324,710 is a formulation-specific method patent for once-daily tretinoin lotion treatment of acne vulgaris.
The core claim requires tretinoin, two defined acrylic polymer systems, soluble collagen, sodium hyaluronate, oil, water, and a lotion dosage form.
Claims 2 and 14 focus on a commercially important 0.05% tretinoin formulation.
The patent does not broadly cover all tretinoin products or all acne treatments.
A generic cream, gel, microsphere product, or materially different lotion may avoid literal infringement.
Altreno is the principal commercial product associated with the claimed technology.
The expected family-level patent horizon is approximately June 2035, subject to the official patent-term calculation and Orange Book record.
Paragraph IV risk is highest for a direct Altreno formulation copy.
Biosimilar competition is not relevant because tretinoin is a small-molecule drug.
The principal design-around opportunities involve the emulsifier, viscosity agent, moisturizing system, oil phase, dosage form, and labeling.

Frequently Asked Questions

Does Patent 11,324,710 cover generic tretinoin cream?

No. The claims require a lotion containing a defined polymeric emulsifier, viscosity agent, soluble collagen, sodium hyaluronate, oil, and water. A conventional tretinoin cream is not automatically within the claims.

Does the patent cover tretinoin gel?

Generally no, unless the gel is legally construed as satisfying the claimed lotion limitation and also contains every required composition element. A conventional tretinoin gel would normally present a lower literal-infringement risk.

Is 0.05% tretinoin alone enough to infringe?

No. The 0.05% concentration is only one limitation. The product must also satisfy the polymer, moisturizer, oil, water, lotion, dosing, and acne-treatment limitations.

Can a generic omit soluble collagen to avoid the patent?

Omitting soluble collagen would provide a strong literal noninfringement position because claim 1 requires a moisturizing agent comprising soluble collagen and sodium hyaluronate. Doctrine-of-equivalents risk would depend on the substitute ingredient and the prosecution history.

What is the most important claim for Altreno competition?

Claim 14 is the most commercially targeted claim because it identifies a 0.05% tretinoin formulation with carbomer copolymer type B, carbomer homopolymer type A, mineral oil, glycerin, butylated hydroxytoluene, octoxynol-9, and optional preservatives and trolamine.

References

U.S. Patent No. 11,324,710. (2022). Tretinoin pharmaceutical compositions and methods of use. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2018). Altreno (tretinoin) lotion, 0.05%: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Code, 21 U.S.C. § 355(j). Abbreviated applications for new drugs.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension information. USPTO.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dow Pharm	ALTRENO	tretinoin	LOTION;TOPICAL	209353-001	Aug 23, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	114730	⤷ Start Trial
Brazil	112020020431	⤷ Start Trial
Canada	3095937	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,324,710

Which drugs does patent 11,324,710 protect, and when does it expire?

Summary for Patent: 11,324,710